Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The T-type calcium channel protein subunit alpha-1G (CACNA1G), also known as Cav3.1, is a voltage-dependent, low-voltage activated (LVA) calcium channel subunit that forms the pore of the T-type calcium channels. It is highly expressed in the brain, heart, kidney and lung. It is crucial for pacemaking activity in central neurons and cardiac nodal cells and is involved in neuronal oscillations important for sleep rhythms and absence seizures. Dysfunction or altered expression of CACNA1G/Cav3.1 has been implicated in absence epilepsy/absence seizures, sleep disorders involving thalamocortical dysrhythmias, and cardiac arrhythmias. Blockade of this channel subtype is an established therapeutic strategy against absence epilepsy.
T-type calcium channel blockade
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-type Calcium Channel Protein Subunit Alpha-1G (CACNA1G).